Higher frequencies of circulating CD8+ T cells with a CD57+ CD28− KLRG1+ phenotype, indicating late‐stage differentiation and immunosenescence, were strongly associated with worse response, mPFS (1.7 vs. 3.8 months), and mOS (3.1 vs. 20.8 months) after multivariate regression in advanced NSCLC patients given single‐agent αPD‐(L)1 in both discovery and validation cohorts (Figure 3B).61 The gene discussed is CD8A; the disease is non-small cell lung carcinoma.